Molnupiravir To Reach 105 LMICs Through MPP Agreement
Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral
Executive Summary
Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.
You may also be interested in...
Challenges Remain For Off-Patent Industry’s COVID Response
At an symposium convened by the WHO, WIPO and WTO, the IGBA has highlighted ongoing challenges for the off-patent industry’s continuing response to the COVID-19 pandemic.
MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”